[go: up one dir, main page]

DE69636544D1 - Expression von lipoproteinen - Google Patents

Expression von lipoproteinen

Info

Publication number
DE69636544D1
DE69636544D1 DE69636544T DE69636544T DE69636544D1 DE 69636544 D1 DE69636544 D1 DE 69636544D1 DE 69636544 T DE69636544 T DE 69636544T DE 69636544 T DE69636544 T DE 69636544T DE 69636544 D1 DE69636544 D1 DE 69636544D1
Authority
DE
Germany
Prior art keywords
protein
lipidated
disclosed
leader sequence
heterologous
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69636544T
Other languages
English (en)
Other versions
DE69636544T2 (de
Inventor
C Huebner
F Erdile
J Warakomski
S Becker
Maryanne B Gray
L Pyle
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Pasteur Inc
Original Assignee
Sanofi Pasteur Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Pasteur Inc filed Critical Sanofi Pasteur Inc
Application granted granted Critical
Publication of DE69636544D1 publication Critical patent/DE69636544D1/de
Publication of DE69636544T2 publication Critical patent/DE69636544T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C12N15/625—DNA sequences coding for fusion proteins containing a sequence coding for a signal sequence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/205—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Campylobacter (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE69636544T 1995-06-07 1996-06-05 Expression von lipoproteinen Expired - Lifetime DE69636544T2 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US47578195A 1995-06-07 1995-06-07
US48637395A 1995-06-07 1995-06-07
US475781 1995-06-07
US486373 1995-06-07
PCT/IB1996/000633 WO1996040718A1 (en) 1995-06-07 1996-06-05 Expression of lipoproteins

Publications (2)

Publication Number Publication Date
DE69636544D1 true DE69636544D1 (de) 2006-10-26
DE69636544T2 DE69636544T2 (de) 2007-06-06

Family

ID=27044930

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69636544T Expired - Lifetime DE69636544T2 (de) 1995-06-07 1996-06-05 Expression von lipoproteinen

Country Status (13)

Country Link
EP (2) EP0832093B1 (de)
JP (1) JP4091112B2 (de)
AT (1) ATE339436T1 (de)
AU (1) AU721954B2 (de)
CA (2) CA2223300C (de)
DE (1) DE69636544T2 (de)
DK (1) DK0832093T3 (de)
ES (1) ES2271954T3 (de)
FI (1) FI974422L (de)
IL (1) IL118578A (de)
NO (2) NO324089B1 (de)
PT (1) PT832093E (de)
WO (1) WO1996040718A1 (de)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7008625B2 (en) 1993-11-01 2006-03-07 Research Foundation Of The State University Of New York Recombinant constructs of Borrelia burgdorferi
ZA964896B (en) * 1995-06-07 1997-01-08 Connaught Lab Expression of lipoproteins
AU2003204215B2 (en) * 1998-02-03 2007-01-11 Aventis Pasteur Recombinant Lipidated PsaA Protein, Methods of Preparation and Use
WO1999040200A1 (en) * 1998-02-03 1999-08-12 Center For Disease Control And Prevention RECOMBINANT LIPIDATED PsaA PROTEIN, METHODS OF PREPARATION AND USE
EP1790660B1 (de) * 2000-02-28 2012-06-20 Novartis Vaccines and Diagnostics S.r.l. Heterologe Expression von Neisseria Proteinen
EP1311540B1 (de) 2000-08-18 2007-12-19 Research Foundation Of State University Of New York Veränderte borrelia burgdorferi ospa
MY144532A (en) 2001-08-20 2011-09-30 Lundbeck & Co As H Novel method for down-regulation of amyloid
MX339524B (es) 2001-10-11 2016-05-30 Wyeth Corp Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
DK1812058T3 (da) 2004-10-25 2012-09-17 Statens Seruminstitut Chlamydia Trachomatis antigener til vaccine og diagnostisk anvendelse
CA2836319A1 (en) 2005-06-23 2006-12-28 Statens Serum Institut Tuberculosis vaccines comprising antigens expressed during the latent infection phase
CA2936822C (en) 2006-01-19 2021-09-14 Mary Kay, Inc. Skin care compositions comprising kakadu plum extract
US20090324638A1 (en) * 2006-06-12 2009-12-31 Biopeptides Corp. Live bacterial vaccine
AR064642A1 (es) 2006-12-22 2009-04-15 Wyeth Corp Polinucleotido vector que lo comprende celula recombinante que comprende el vector polipeptido , anticuerpo , composicion que comprende el polinucleotido , vector , celula recombinante polipeptido o anticuerpo , uso de la composicion y metodo para preparar la composicion misma y preparar una composi
PL2199303T3 (pl) 2008-12-12 2013-11-29 Euroimmun Medizinische Labordiagnostika Ag Polipeptydy i sposoby swoistego wykrywania przeciwciał u pacjentów z zakażeniem krętkami Borrelia
AU2010238943B9 (en) 2009-04-24 2015-10-15 Statens Serum Institut A tuberculosis TB vaccine to prevent reactivation
KR101772139B1 (ko) 2009-08-28 2017-08-28 마리 케이 인코포레이티드 피부 케어 제형
MX350142B (es) 2010-08-23 2017-08-28 Wyeth Llc * Formulaciones estables de antigenos rlp2086 de neisseria meningitidis.
SG187912A1 (en) 2010-09-10 2013-04-30 Wyeth Llc Non-lipidated variants of neisseria meningitidis orf2086 antigens
SA115360586B1 (ar) 2012-03-09 2017-04-12 فايزر انك تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها
KR101763625B1 (ko) 2012-03-09 2017-08-01 화이자 인코포레이티드 수막염균 조성물 및 이의 사용 방법
WO2014136064A2 (en) 2013-03-08 2014-09-12 Pfizer Inc. Immunogenic fusion polypeptides
CA2923129C (en) 2013-09-08 2020-06-09 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
CN107249626A (zh) 2015-02-19 2017-10-13 辉瑞大药厂 脑膜炎奈瑟球菌组合物及其方法
PE20191107A1 (es) 2017-01-31 2019-08-26 Pfizer Composiciones de neisseria meningitidis y metodos respectivos
CA3155669A1 (en) 2019-09-27 2021-04-01 Pfizer Inc. Neisseria meningitidis compositions and methods thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4624926A (en) * 1981-01-02 1986-11-25 The Research Foundation Of State University Of New York Novel cloning vehicles for polypeptide expression in microbial hosts
WO1993008306A1 (en) * 1991-10-22 1993-04-29 Symbicom Aktiebolag Improvement in borrelia burgdorferi diagnosis and prophylaxis
CA2032914A1 (en) * 1989-12-26 1991-06-27 Peter C.K. Lau Use of bacterial lipoprotein amino terminus in fusion plasmids for in vivo expression of lipid modified polypeptides
SG47447A1 (en) * 1990-06-15 1998-04-17 Univ Yale Compositions and methods for the prevention and diagnosis of lyme disease
ZA921025B (en) * 1991-02-15 1992-11-25 Uab Research Foundation Structural gene of pneumococcal protein
AU5958594A (en) * 1992-12-24 1994-07-19 Med Immune, Inc. Method of protection against (streptococcus pneumoniae) with transformed mycobacteria

Also Published As

Publication number Publication date
EP0832093A1 (de) 1998-04-01
DE69636544T2 (de) 2007-06-06
DK0832093T3 (da) 2007-01-08
EP1741718A3 (de) 2007-03-28
FI974422A7 (fi) 1998-02-04
AU721954B2 (en) 2000-07-20
IL118578A (en) 2006-12-31
EP1741718A2 (de) 2007-01-10
ES2271954T3 (es) 2007-04-16
EP0832093A4 (de) 2001-01-03
FI974422A0 (fi) 1997-12-05
ATE339436T1 (de) 2006-10-15
NO20064621L (no) 1998-01-30
JPH11514841A (ja) 1999-12-21
AU6134396A (en) 1996-12-30
NO975619L (no) 1998-01-30
NO324089B1 (no) 2007-08-13
JP4091112B2 (ja) 2008-05-28
EP0832093B1 (de) 2006-09-13
PT832093E (pt) 2006-12-29
CA2223300C (en) 2010-07-27
CA2704354A1 (en) 1996-12-19
CA2223300A1 (en) 1996-12-19
WO1996040718A1 (en) 1996-12-19
FI974422L (fi) 1998-02-04
IL118578A0 (en) 1996-10-16
NO975619D0 (no) 1997-12-04

Similar Documents

Publication Publication Date Title
DE69636544D1 (de) Expression von lipoproteinen
DK0737207T3 (da) Inhibitorer for humant plasmin afledt af Kunitz-domæner
DE68917323D1 (de) Expressions-Vektor für Fusions-Proteine und Immunogen-Proteine.
IT8520226A0 (it) Sistema di controllo per motore commutato elettronicamente, sistema di motore commutato elettronicamente, macchina lavabiancheria e metodi per controllare la medesima.
FI956075L (fi) Rekombinantti, ihon sarveiskerroksen kymotyptinen entsyymi (SCCE)
EP0608120A3 (de) Durchflusssteuerungsvorrichtung für Kapillarelektroforese.
HUT77049A (hu) Katepszin-02-fehérjék, -nukleinsavak és -ellenanyagok
ATE263836T1 (de) Chimere proteine, welche borrelia polypeptide beinhalten, verwendungen dafür
FI972384A7 (fi) Uudet dipeptidiset p-amidinobentsyyliamidit, jotka sisältävät N-termin aalisia sulfonyyli- tai amidinosulfonyyliryhmiä
IT1307309B1 (it) Peptidi stabilizzanti, polipeptidi ed anticorpi che li comprendono.
NL1006820A1 (nl) Stabilisatormengsels.
NL193766B (nl) Geïsoleerde draad.
DK295188A (da) Fibronectinbindende protein og fremgangsmaade til fremstilling heraf
DE69902796D1 (de) Verfahren zur reinigung von biomolekül- oder proteinkomplexen
DE19681312T1 (de) Datenverbindungs-Steuerverfahren
HU9202074D0 (en) Collagen binding protein qnd method for producing it
SE9602822D0 (sv) New receptor
FI952738L (fi) Stabiiliproteiini, fosfolipidikoostumuksia ja menetelmiä
EP0612847A3 (de) Antimikrobielle Proteine.
DE59000427D1 (de) Antriebsschlupfregelsystem.
NO892948L (no) Modifiserte proteiner.
DE3484304D1 (de) Streptokinase kodierende rekombinante vektoren.
NL1005505A1 (nl) Servobesturingsinrichting.
SE9302856D0 (sv) Method and means for producing a plasmapeotein-binding protein
PT101187A (pt) Sistema de controlo de viseiras de mascaras ou oculos no punho do alicate de maquina ou macarico de soldadura

Legal Events

Date Code Title Description
8364 No opposition during term of opposition